Compile Data Set for Download or QSAR
Report error Found 176 Enz. Inhib. hit(s) with all data for entry = 11913
TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660387BDBM660387(US20240092799, Compound XXIV-G)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660381BDBM660381(US20240092799, Compound XXIV-A)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660382BDBM660382(US20240092799, Compound XXIV-B | US20240092799, Co...)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660382BDBM660382(US20240092799, Compound XXIV-B | US20240092799, Co...)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660389BDBM660389(US20240092799, Compound XXIV-I)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660391BDBM660391(US20240092799, Compound XXIV-K)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660369BDBM660369(US20240092799, Compound XXIII-P)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660493BDBM660493(US20240092799, Compound XXXI)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660494BDBM660494(US20240092799, Compound XXXI-A)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660378BDBM660378(US20240092799, Compound XXIII-Y)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660373BDBM660373(US20240092799, Compound XXIII-T)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660374BDBM660374(US20240092799, Compound XXIII-U)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660417BDBM660417(US20240092799, Compound XXVIII-P)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660416BDBM660416(US20240092799, Compound XXVIII-O)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660419BDBM660419(US20240092799, Compound XXVIII-R)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660418BDBM660418(US20240092799, Compound XXVIII-Q)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660413BDBM660413(US20240092799, Compound XXVIII-L)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660412BDBM660412(US20240092799, Compound XXVIII-K)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660414BDBM660414(US20240092799, Compound XXVIII-M)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660424BDBM660424(US20240092799, Compound XXIX-AN | US20240092799, C...)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660427BDBM660427(US20240092799, Compound XXIX-G)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660426BDBM660426(US20240092799, Compound XXIX-F)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660421BDBM660421(US20240092799, Compound XXIX-A)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660420BDBM660420(US20240092799, Compound XXIX)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660401BDBM660401(US20240092799, Compound XXVIII)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660403BDBM660403(US20240092799, Compound XXVIII-B)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660338BDBM660338(US20240092799, Compound XVII-A | US20240092799, Co...)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660409BDBM660409(US20240092799, Compound XXVIII-H)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660408BDBM660408(US20240092799, Compound XXVIII-G)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660404BDBM660404(US20240092799, Compound XXVIII-C)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660325BDBM660325(US20240092799, Compound IIa)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660451BDBM660451(US20240092799, Compound XXIX-AE)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660325BDBM660325(US20240092799, Compound IIa)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660450BDBM660450(US20240092799, Compound XXIX-AD)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660447BDBM660447(US20240092799, Compound XXIX-AA)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660446BDBM660446(US20240092799, Compound XXIX-Z)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660459BDBM660459(US20240092799, Compound XXIX-AM)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660458BDBM660458(US20240092799, Compound XXIX-AL)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660326BDBM660326(US20240092799, Compound IIb)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 1(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660326BDBM660326(US20240092799, Compound IIb)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660452BDBM660452(US20240092799, Compound XXIX-AF)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660454BDBM660454(US20240092799, Compound XXIX-AH)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660431BDBM660431(US20240092799, Compound XXIX-K)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660481BDBM660481(US20240092799, Compound XXIX-AAI)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660483BDBM660483(US20240092799, Compound XXIX-AAK)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660482BDBM660482(US20240092799, Compound XXIX-AAJ)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660477BDBM660477(US20240092799, Compound XXIX-AAE)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660348BDBM660348(US20240092799, Compound XX-D)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660476BDBM660476(US20240092799, Compound XXIX-AAD)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

TargetMAP kinase-interacting serine/threonine-protein kinase 2(Human)
Hepagene Therapeutics (Hk

US Patent
LigandChemical structure of BindingDB Monomer ID 660351BDBM660351(US20240092799, Compound XXI-A)
Affinity DataIC50: 5.5nMAssay Description:This protocol establishes the binding assays for MNK1 and MNK2 using ADP-Glo assay. MNK phosphorylates the substrate and converts ATP to ADP, which w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
US Patent

Displayed 1 to 50 (of 176 total ) | Next | Last >>
Jump to: